Morning Briefing
Summaries of health policy coverage from major news organizations
Merck Could Lose Patent on Key Drug Singulair
Merck & Co. could lose it's exclusive right to market Singulair early, a successful allergy treatment with patent protection set to expire in 2012.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
